BVS Experts Survey 2015 now published

BVS Experts Survey 2015 now published

This is the article just published in JACC as a Research Letter. It refers to the Survey that we conducted in 2015 and that was reserved to the most influencing experts on the Absorb BVS technology.

As you are probably aware, the FDA gave green light to Absorb to be sold in the US, so knowing what Experts do really think about BVS, specifically for the scaffold thrombosis issue, if of some importance.

Please, take your time to read alsoJAC_22510 the comments on the Survey made by Michael O’Riordan in TCTMD:

http://www.tctmd.com/show.aspx?id=135417&utm_source=TCTMD_News_062016&utm_medium=email&utm_campaign=TCTMD_Weekly_Newsbrief

EuroPCR coverage 2

EuroPCR coverage 2

This is MATRIX time @ EuroPCR 2016.

I had the privilege of presenting one of the most important subsidies of the Matrix trial, PI Marco Valgimigli, assessing the role of transradial vs. transfemoral PCI either in STEMI or NSTE-ACS patients undergoing invasive management.

Results were consistent with the main publication in Lancet last year, showing a significant benefit in terms of NACE and a strong trend in terms of improvement of MACE for the transradial approach.

EuroPCR coverage 1

EuroPCR coverage 1

This is the official TCTMD report on the late-breaking clinical trial session on BVS at the latest EuroPCR.

I am proud of being part of it, presenting the short-term data of the RAI registry. And I am also proud that our centre was the second top enroller centre in both the RAI and IT-DISAPPEARS registry!

http://www.tctmd.com/show.aspx?id=135200